Response to ‘Kidney Disease in Moderate-To-Severe Psoriasis: A Critical Appraisal’

British Journal of Dermatology - United Kingdom
doi 10.1111/bjd.14304
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Transition to Ustekinumab in Patients With Moderate-To-Severe Psoriasis and Inadequate Response to Methotrexate: A Randomized Clinical Trial (TRANSIT)

British Journal of Dermatology
DermatologyMedicine
2014English

Ixekizumab Efficacy and Safety in Moderate-To-Severe Genital Psoriasis

British Journal of Dermatology
DermatologyMedicine
2018English

New Polymorphisms Associated With Response to Anti-TNF Drugs in Patients With Moderate-To-Severe Plaque Psoriasis

Pharmacogenomics Journal
Molecular MedicineGeneticsPharmacology
2016English

Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis

Archives of Dermatology
2004English

Characterization of Insufficient Responders to Ustekinumab in Patients With Moderate-To-Severe Psoriasis in the US Corrona Psoriasis Registry

Journal of Dermatological Treatment
Dermatology
2020English

Population Pharmacokinetics of Brodalumab in Patients With Moderate to Severe Plaque Psoriasis

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2019English

A Policy Model of Cardiovascular Disease in Moderate-To-Advanced Chronic Kidney Disease

Heart
Cardiovascular MedicineCardiology
2017English

Oral Curcumin in the Treatment of Moderate to Severe Psoriasis Vulgaris: A Prospective Clinical Trial

Journal of the American Academy of Dermatology
Dermatology
2008English

Ustekinumab in Real-Life Practice: Experience in 116 Patients With Moderate-To-Severe Psoriasis

Acta Medica Portuguesa
Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy